
FDA Accepts Inhibrx Biologics License Application for Ozekibart
The U.S. Food and Drug Administration has accepted Inhibrx Biosciences' application for ozekibart, a potential treatment for unresectable or metastatic conventional chondrosarcoma. With no filing review issues identified, the agency has set a Prescription Drug User Fee Act goal date of April 14, 2027, for its final decision.



























